The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
Open accessAbstract
NTRK1, NTRK2 and NTRK3 fusions have been reported in a plethora of malignancies across different histologies and represent the most common mechanism of oncogenic activation of these receptor tyrosine kinases. These fusions result in chimaeric genes, where the 3' region of NTRK is joined with a 5' sequence of a fusion partner, resulting in a constitutively activated TRK with oncogenic properties. NTRK fusions have emerged as new targets for cancer therapy as they can be successfully inhibited by small molecule kinase inhibitors leading to durable responses across disease sites. Given the multitude of partners involved in NTRK1/2/3 fusions, crucial to the administration of NTRK inhibitors is the development of optimal approaches for the detection of human cancers harbouring activating NTRK1/2/3 fusion genes. The main techniques employed for NTRK fusion gene detection include immunohistochemistry, fluorescence in situ hybridization, RT-PCR, and both RNA-based and DNA-based next-generation sequencing. Each technique has advantages and limitations, and the choice of assays for screening and final diagnosis should also take into account the resources and clinical context. The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods for the detection of NTRK gene fusions, their potential applications, and strategies for the implementation of a rational approach for the detection of NTRK1/2/3 fusion genes in human malignancies. We present here recommendations for the routine clinical detection of targetable NTRK1/2/3 fusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 2×
“[13] have reported on the use of MSK-IMPACT in a prospective clinical sequencing of unselected metastatic patients and NTRK1 and NTRK3 fusions were detected in 18 patients (0.”
BackgroundMethodSelf-citationEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationNeurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Self-citationSkálová, A., Vanecek, T., Sima, R., Laco, J., Weinreb, I., Perez-Ordonez, B., Starek, I., Geierova, M., Simpson, R. H., Passador-Santos, F., et al. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,023
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C., Knezevich, S. R., Huntsman, D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L., Carneiro, F., MacPherson, N., Horsman, D., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 911
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
Knezevich, S. R., McFadden, D. E., Tao, W., Lim, J. F., & Sorensen, P. H. B. (1998) · Nature Genetics · doi:10.1038/ng0298-184 · Cited by 800
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Amatu, A., Sartore-Bianchi, A., & Siena, S. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000023 · Cited by 601
Laetsch, T. W., DuBois, S. G., Mascarenhas, L., Turpin, B., Federman, N., Albert, C. M., Nagasubramanian, R., Davis, J. L., Rudzinski, E., Feraco, A. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30119-0 · Cited by 552
The integrated landscape of driver genomic alterations in glioblastoma
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2734 · Cited by 524
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504 · cited 14×
“Pietrantonio F, Di Nicolantonio F, Schrock AB et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer.”
BackgroundInfluentialTrk receptor tyrosine kinases: A bridge between cancer and neural development
Nakagawara, A. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00530-4 · Cited by 495
Oncogenes in solid human tumours
Pulciani, S., Santos, E., Lauver, A. V., Long, L. K., Aaronson, S. A., & Barbacid, M. (1982) · Nature · doi:10.1038/300539a0 · Cited by 478
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Hechtman, J. F., Benayed, R., Hyman, D. M., Drilon, A., Zehir, A., Frosina, D., Arcila, M. E., Dogan, S., Klimstra, D. S., Ladanyi, M., et al. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000911 · Cited by 468
Self-citationDrilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 439
Self-citationKnezevich, S. R., Garnett, M. J., Pysher, T. J., Beckwith, J. B., Grundy, P. E., & Sorensen, P. H. B. (1998) · PubMed · Cited by 412
Qaddoumi, I., Orisme, W., Wen, J., Santiago, T., Gupta, K., Dalton, J. D., Tang, B., Haupfear, K., Punchihewa, C., Easton, J., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1539-z · Cited by 409
Doebele, R. C., Davis, L. E., Vaishnavi, A., Le, A. T., Estrada-Bernal, A., Keysar, S., Jimeno, A., Varella-Garcia, M., Aisner, D. L., Li, Y., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0443 · Cited by 388
Bourgeois, J. M., Knezevich, S. R., Mathers, J. A., & Sorensen, P. H. B. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200007000-00005 · Cited by 338
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Pietrantonio, F., Di Nicolantonio, F., Schrock, A. B., Lee, J., Tejpar, S., Sartore-Bianchi, A., Hechtman, J. F., Christiansen, J., Novara, L., Tebbutt, N., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx089 · Cited by 317
Self-citationAcquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Russo, M., Misale, S., Wei, G., Siravegna, G., Crisafulli, G., Lazzari, L., Corti, G., Rospo, G., Novara, L., Mussolin, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0940 · Cited by 308
Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D. M., Hechtman, J., Wei, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw042 · Cited by 306
Self-citationFusion of ETV6 to Neurotrophin-3 Receptor TRKC in Acute Myeloid Leukemia With t(12;15)(p13;q25)
Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1355 · Cited by 281
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma
Chiang, S., Cotzia, P., Hyman, D. M., Drilon, A., Tap, W. D., Zhang, L., Hechtman, J. F., Frosina, D., Jungbluth, A. A., Murali, R., et al. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001055 · Cited by 242
Self-citationDurable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Farago, A. F., Le, L. P., Zheng, Z., Muzikansky, A., Drilon, A., Patel, M., Bauer, T. M., Liu, S. V., Ou, S.-H. I., Jackman, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000473485.38553.f0 · Cited by 229
Self-citationTomasson, M. H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., Ries, R. E., Lubman, O., Fremont, D. H., McLellan, M. D., et al. (2008) · Blood · doi:10.1182/blood-2007-09-113027 · Cited by 227
Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors
Rudzinski, E. R., Lockwood, C. M., Stohr, B. A., Vargas, S. O., Sheridan, R., Black, J. O., Rajaram, V., Laetsch, T. W., & Davis, J. L. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001062 · Cited by 213
Skálová, A., Vanecek, T., Simpson, R. H. W., Laco, J., Majewska, H., Baneckova, M., Steiner, P., & Michal, M. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000537 · Cited by 193
Rearrangements of NTRK1 gene in papillary thyroid carcinoma
Greco, A., Miranda, C., & Pierotti, M. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.009 · Cited by 190
Cocco, E., Benhamida, J., Middha, S., Zehir, A., Mullaney, K., Shia, J., Yaeger, R., Zhang, L., Wong, D., Villafania, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3126 · Cited by 163
Self-citationThe ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
Wai, D. H., Knezevich, S. R., Lucas, T., Jansen, B., Kay, R. J., & Sorensen, P. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203396 · Cited by 162
Church, A. J., Calicchio, M. L., Nardi, V., Skálová, A., Pinto, A., Dillon, D. A. R., Gomez-Fernandez, C. R., Manoj, N., Haimes, J. D., Stahl, J. A., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.127 · Cited by 158
Tognon, C. E., Garnett, M. J., Kenward, E., Kay, R., Morrison, K. B., & Sorensen, P. H. B. (2001) · PubMed · Cited by 154
Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer
Yu, X., Liu, L., Cai, B., He, Y., & Wan, X. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00722.x · Cited by 121
The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium
Russell, J. P., Powell, D. J., Cunnane, M. F., Greco, A., Portella, G., Santoro, M. M., Fusco, A., & Rothstein, J. L. (2000) · Oncogene · doi:10.1038/sj.onc.1203922 · Cited by 111
Identification of NTRK fusions in pediatric mesenchymal tumors
Pavlick, D. C., Schrock, A. B., Malicki, D. M., Stephens, P. J., Kuo, D. J., Ahn, H., Turpin, B. K., Allen, J. M., Rosenzweig, M. R., Badizadegan, K., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26433 · Cited by 105
Castillo, M. D., Chibon, F., Arnould, L., Croce, S., Ribeiro, A., Pérot, G., Hostein, I., Geha, S., Bozon, C., Garnier, A., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000487 · Cited by 100
Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia
Kralik, J. M., Kranewitter, W. J., Bösmüller, H. C., Marschon, R., Tschurtschenthaler, G., Rumpold, H. F., Wiesinger, K., Erdel, M., Petzer, A. L., & Webersinke, G. (2011) · Diagnostic Pathology · doi:10.1186/1746-1596-6-19 · Cited by 98
Primary and Metastatic Melanoma With NTRK Fusions
Lezcano, C. M., Shoushtari, A. N., Ariyan, C. E., Hollmann, T. J., & BUSAM, K. J. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001070 · Cited by 96
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
Tao, J. J., Schram, A. M., & Hyman, D. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062016-050343 · Cited by 89
Murphy, D. A., Ely, H. A., Shoemaker, R., Boomer, A., Culver, B. P., Hoskins, I., Haimes, J. D., Walters, R. D., Fernandez, D., Stahl, J. A., et al. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000360 · Cited by 85
Coulier, F., Kumar, R., Ernst, M. K., Klein, R., Martín-Zanca, D., & Barbacid, M. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.8.4202-4210.1990 · Cited by 81
Marchetti, A., Felicioni, L., Pelosi, G., Grammastro, M. D., Fumagalli, C., Sciarrotta, M., Malatesta, S., Chella, A., Barassi, F., Mucilli, F., et al. (2008) · Human Mutation · doi:10.1002/humu.20707 · Cited by 80
A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing
Beadling, C., Wald, A. I., Warrick, A., Neff, T. L., Zhong, S., Nikiforov, Y. E., Corless, C. L., & Nikiforova, M. N. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.10.002 · Cited by 79
Drilon, A. E. D. C., DuBois, S. G., Farago, A. F., Geoerger, B., Grilley‐Olson, J. E., Hong, D. S., Sohal, D. P. S., van Tilburg, C. M., Ziegler, D. S., Ku, N. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2006 · Cited by 79
Demetri, G. D., Paz-Ares, L. G., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C. M., Krauss, J. C., Sigal, D. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.017 · Cited by 71
Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma
Wadhwa, S., Nag, T. C., Jindal, A., Kushwaha, R. C., Mahapatra, A. K., & Sarkar, C. (2003) · Journal of Biosciences · doi:10.1007/bf02706217 · Cited by 64
Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer
Harada, T., Yatabe, Y., Takeshita, M., Koga, T., Yano, T., Wang, Y., & Giaccone, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3034 · Cited by 61
Functional Characterization of Human Cancer-Derived TRKB Mutations
Geiger, T. R., Song, J., Rosado, A., & Peeper, D. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016871 · Cited by 58
Kim, J., Kim, S., Ko, S., In, Y.-H., Moon, H., Ahn, S. K., Kim, M. K., Lee, M., Hwang, J., Ju, Y. S., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22279 · Cited by 53
Tacconelli, A., Farina, A. R., Cappabianca, L. A., Gulino, A., & Mackay, A. R. (2005) · Future Oncology · doi:10.2217/14796694.1.5.689 · Cited by 53
Milione, M., Ardini, E., Christiansen, J., Valtorta, E., Veronese, S. M., Bosotti, R., Pellegrinelli, A., Testi, A., Pietrantonio, F., Fucà, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19512 · Cited by 34
Tatematsu, T., Sasaki, H., Shimizu, S., Okuda, K., Shitara, M., Hikosaka, Y., Moriyama, S., Yano, M., Brown, J. S., & Fujii, Y. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.318 · Cited by 32
Functional characterization of NTRK1 mutations identified in melanoma
Miranda, C., Mazzoni, M., Sensi, M., Pierotti, M. A., & Greco, A. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22200 · Cited by 29
Conde, E., Caminoa, A., Domínguez, C., Calles, A., Walter, S., Angulo, B., Sánchez, E., Alonso, M., Jimenez, L., Madrigal, L. Í., et al. (2017) · Histopathology · doi:10.1111/his.13346 · Cited by 21
Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
van Tilburg, C. M., DuBois, S. G., Albert, C. M., Federman, N. C., Nagasubramanian, R., Geoerger, B., Orbach, D. H., Bielack, S., Shukla, N. N., Turpin, B. K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.10010 · Cited by 20
Larotrectinib efficacy and safety in adult TRK fusion cancer patients.
Hong, D. S., Kummar, S., Farago, A. F., Lassen, U., Berlin, J. D., Schilder, R. J., McDermott, R., Patel, J., Dowlati, A., Doebele, R. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3122 · Cited by 10
Cited by
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Self-citationHendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
Pathogenesis of Triple-Negative Breast Cancer
Derakhshan, F., & Reis-Filho, J. S. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-093238 · Cited by 714
Self-citation
Metadata
- Authors
- Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A. J., Bibeau, F., Dietel, M., Hechtman, J. F., Troiani, T., López-Rios, F., Douillard, J.-Y., Andrè, F., & Reis-Filho, J. S.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 30
- Issue
- 9
- Pages
- 1417-1427
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2953495640
- Cited by
- 372
- References
- 62
- FWCI
- 35.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.